primary%20biliary%20cholangitis
PRIMARY BILIARY CHOLANGITIS

Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


 

  1. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000 Apr;31(4):1005-1013. PMID: 10733559
  2. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev. 2004 Feb:CD004481. PMID: 15106254
  3. Pratt DS. Cholestasis and cholestatic syndromes. Curr Opin Gastroenterol. 2005 May;21(3):270-274. PMID: 15818146
  4. Oo YH, Neuberger J. Options for the treatment of primary biliary cirrhosis. Drugs. 2004;64(20):2261-2271. PMID: 15456326
  5. Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst Rev. 2005 Apr;(2):CD003778. PMID: 15846681
  6. Feldman M, Friedman LS, Sleisenger MH, eds. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology/diagnosis/management. 7th ed. Pennsylvania: Saunders; 2002
  7. MedWormhttp://www.medworm.com/rss/index.php/Gastroenterology/17/http://www.medworm.com/rss/medicalfeeds/specialities/Gastroenterology.xml
  8. Pyrsopoulos NT, Rajernder Reddy K. Primary biliary cirrhosis. http://emedicine.medscape.com. Sep 2004. Accessed 12 Sep 2005.
  9. Poupon R. Overview of the treatment of primary biliary cirrhosis. UpToDate. http://www.uptodate.com. 16 Jul 2013. Accessed 13 Mar 2014.
  10. Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis. Hepatology Research. 2014;44(Suppl 1):71–90. doi: 10.1111/hepr.12270. Accessed 12 Mar 2014
  11. Civan JM. Cirrhosis. The Merck Manual. http://www.merckmanuals.com. Jul 2013.
  12. Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol. 2015 May 8;7(7):926-941. doi: 10.4254/wjh.v7.i7.926. PMID: 25954476
  13. European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. PMID: 28427765
  14. Lindor KD, Bowlus CL, Boyer J, et al. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019 Jan;69(1):394-419. doi: 10.1002/hep.30145. PMID: 30070375
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
11 Sep 2019
Blood pressure (BP) in children is influenced by early-life exposure to several chemicals, built environment and meteorological factors, suggests a study.
Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.